SEC Comment Letter for INSMED Inc (INSM) (CIK 0001104506) (INSM) — Jan 14, 2020
INSMED Inc (INSM) (CIK 0001104506)
Date: Jan. 14, 2020 · CIK: 0001104506 · Accession: 0000000000-20-000342
AI Filing Summary & Sentiment
File numbers found in text: 000-30739
Referenced dates: December 4, 2019
Letter
January 14, 2020 John Goll Chief Accounting Officer INSMED Inc 10 Finderne Avenue, Building 10 Bridgewater, NJ. 08807 Re:INSMED Inc Form 10-K filed on February 22, 2019 Filed on February 22, 2019 Form 8-K filed on October 30, 2019 File no. 000-30739 Dear Mr. Goll: We have limited our review of your filing to the financial statements and related disclosures and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to these comments within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comments apply to your facts and circumstances, please tell us why in your response. After reviewing your response to these comments, we may have additional comments. Form 8-K filed on October 30, 2019 Exhibit 99.1, page 3 1.We note your response to our comment from our letter dated December 4, 2019. In order to distinguish your Arikayce milestone payments from your other more typical milestone payments, please expand your disclosures to highlight the nature of your research funding arrangement with the Cystic Fibrosis Foundation and how the arrangement differs from your other license agreements. In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. You may contact Ameen Hamady at 202-551-3891 or in his absence, Jeanne Baker at 202-551-3691 with any questions.
FirstName LastNameJohn Goll Comapany NameINSMED Inc January 14, 2020 Page 2 FirstName LastName John Goll INSMED Inc January 14, 2020 Page 2 Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
January 14, 2020
John Goll
Chief Accounting Officer
INSMED Inc
10 Finderne Avenue, Building 10
Bridgewater, NJ. 08807
Re:INSMED Inc
Form 10-K filed on February 22, 2019
Filed on February 22, 2019
Form 8-K filed on October 30, 2019
File no. 000-30739
Dear Mr. Goll:
We have limited our review of your filing to the financial statements and related
disclosures and have the following comments. In some of our comments, we may ask you to
provide us with information so we may better understand your disclosure.
Please respond to these comments within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe our
comments apply to your facts and circumstances, please tell us why in your response.
After reviewing your response to these comments, we may have additional comments.
Form 8-K filed on October 30, 2019
Exhibit 99.1, page 3
1.We note your response to our comment from our letter dated December 4, 2019. In order
to distinguish your Arikayce milestone payments from your other more typical milestone
payments, please expand your disclosures to highlight the nature of your research funding
arrangement with the Cystic Fibrosis Foundation and how the arrangement differs from
your other license agreements.
In closing, we remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
You may contact Ameen Hamady at 202-551-3891 or in his absence, Jeanne Baker at
202-551-3691 with any questions.
FirstName LastNameJohn Goll
Comapany NameINSMED Inc
January 14, 2020 Page 2
FirstName LastName
John Goll
INSMED Inc
January 14, 2020
Page 2
Sincerely,
Division of Corporation Finance
Office of Life Sciences